Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IKZF2 | Q9UKS7 | 12/20 | 0.73 |
| ▸ | IKZF1 | Q13422 | 2/20 | 0.73 |
| ▸ | CRBN | Q96SW2 | 7/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26609746 | 0.91 | IKZF2 (0.63) | IKZF2IKZF1CRBN | |
| SCHEMBL27061682 | 0.91 | IKZF2 (0.69) | IKZF2IKZF1CRBN | |
| SCHEMBL23105167 | 0.90 | IKZF2 (0.69) | IKZF2IKZF1CRBN | |
| SCHEMBL25010615 | 0.89 | IKZF2 (0.69) | IKZF2IKZF1CRBN | |
| SCHEMBL26609218 | 0.89 | IKZF2 (0.66) | IKZF2IKZF1CRBN | |
| SCHEMBL26609473 | 0.88 | IKZF2 (0.70) | IKZF2IKZF1CRBN | |
| SCHEMBL26609447 | 0.87 | IKZF2 (0.77) | IKZF2IKZF1CRBN | |
| SCHEMBL23509532 | 0.87 | IKZF2 (0.68) | IKZF2IKZF1CRBN | |
| SCHEMBL31144530 | 0.87 | IKZF2 (0.69) | IKZF2IKZF1CRBN | |
| SCHEMBL31144623 | 0.86 | IKZF2 (0.81) | IKZF2IKZF1CRBN |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023178130-A1 | SOS1 PROTEIN DEGRADERS, PHARMACEUTICAL COMPOSITIONS, AND THERAPEUTIC APPLICATIONS | BIOTHERYX, INC. (US) | 2023-09-21 | — | — | WO | disclosed |
| US-20230002371-A1 | RAS PROTEIN DEGRADERS, PHARMACEUTICAL COMPOSITIONS THEREOF, AND THEIR THERAPEUTIC APPLICATIONS | BIOTHERYX INC (US) | 2023-01-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230002371-A1 | RAS PROTEIN DEGRADERS, PHARMACEUTICAL COMPOSITIONS THEREOF, AND THEIR THERAPEUTIC APPLICATIONS | KRAS, RSU1, RAB1A | IKZF2 2454/4885IKZF1 2956/4885CRBN 407/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.